Yes I understand that, but do you imagine the study design will be appreciably different from the sparsentan study? 300 patients to 2 years isn't cheap, and you have to be able to go the distance as interim approval isn't a given, as retrophin saw.
when comparing cost studies remember most pivotal studies in immunology or something like this have primary endpoints at 16-24 weeks, not 108
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA, page-18
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
0.020(4.94%) |
Mkt cap ! $234.0M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 43.3¢ | 42.0¢ | $542.9K | 1.271M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5026 | 42.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 2827 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |